Hyperion Therapeutics Inc., a San Francisco-based drug company focused on gastroenterology and hepatology, has raised $40 million in second-round funding. Sofinnova Ventures led the deal, and was joined by return backers Highland Capital Partners, New Enterprise Associates and WRF Capital. The company raised a $2 million seed round late last year.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.